Building a Phase III-Ready Clinical Leadership Team at Pace

Posted February 19, 2026

Our Approach

We began with a detailed alignment process focused on understanding the ideal candidate profile, and priority.

Working closely with Anthos Leadership, we defined the capabilities, behaviours, and leadership profile required to succeed in a fast-moving and high-accountability environment. We clarified what success looked like across Clinical Operations, Biometrics, Quality, Supply Chain, and TMF, and aligned hiring priorities to Phase III milestones.

A clear Statement of Work was agreed, setting out deliverables, timelines, and direct access to the leadership team. This allowed for fast decision-making, tight feedback loops, and a highly focused search strategy.

Execution

For every role, Elixir delivered a minimum of six highly relevant candidates within four weeks or less. Every appointment was made from the initial shortlist.

Our key point of contact was Sharon Arnold – SVP Development Operations. In her role, Sharon led and integrated Clinical Operations, Biometrics, Clinical Quality, Supply Chain, and TMF.

As the organisation scaled, Elixir partnered with Anthos to build a high-performing clinical and development organisation, delivering hires across the following roles:

  • Director, Clinical Program Lead
  • Executive Director, Clinical Operations
  • Executive Director, Head of Biostatistics and Data Analytics
  • Head of Clinical Quality Management
  • Director, Clinical Supply Management
  • Senior Manager, Site Management
  • Associate Director, Clinical Trial Management
  • Head of Statistical Programming
  • Senior Clinical Trial Associate
  • Senior Clinical Trial Manager
  • Senior Clinical Trial Manager
  • TMF Subject Matter Expert

Outcome

The leadership team assembled during this period re-established control over trial execution, improved site engagement, and accelerated patient enrolment.

Anthos progressed its programs with renewed operational confidence and ultimately achieved a successful acquisition by Novartis for $3.1bn.

The team built during this phase played a critical role in positioning the business to be acquisition-ready on both the clinical and operational fronts.

Client Perspective

I was very impressed with the Elixir team, working closely with Jake Couldrick on all critical hires.  He understood my priorities and the skills and fit that I was looking for.  He and his team were very responsive and timely.  I was extremely happy with the quality of the candidates— we had excellent hires from Elixir.  Our success as a Clinical Operations team was due to our partnership with Elixir.

Sharon Arnold
SVP Development Operations, Anthos Therapeutics

  •  

    Partnering with Anthos to Build a High-Performing Clinical Organisation

    Working closely with leadership, we defined the capabilities, behaviours, and leadership profile required to succeed in a fast-moving and high-accountability environment. We clarified what success looked like across Clinical Operations, Biometrics, Quality, Supply Chain, and TMF, and aligned hiring priorities to Phase III milestones.

    Read More